Targeting mTOR in HIV-negative classic Kaposi's sarcoma

Ofer Merimsky*, Irina Jiveliouk, Ronit Sagi-Eisenberg

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

A 66-year old female with HIV-negative classic Kaposi's sarcoma responded to mTOR targeting by rapamycin. The response was well documented by PET-CT. This case provides supporting evidence that the mTOR pathway may be important in the tumorigenesis of KS and that rapamycin may have activity in this disease.

Original languageEnglish
Article number825093
JournalSarcoma
Volume2008
DOIs
StatePublished - 2008

Fingerprint

Dive into the research topics of 'Targeting mTOR in HIV-negative classic Kaposi's sarcoma'. Together they form a unique fingerprint.

Cite this